Ceftibuten/Ledaborbactam etzadroxil - VenatoRx Pharmaceuticals
Alternative Names: BL/VNRX-7145; Ceftibuten/VNRX-7145; VNRX-7145Latest Information Update: 02 Apr 2025
At a glance
- Originator VenatoRx Pharmaceuticals
- Class 2 ring heterocyclic compounds; Amides; Amines; Antibacterials; Azabicyclo compounds; Beta-lactams; Carboxylic acids; Cephalosporins; Esters; Small molecules; Thiazoles; Urinary anti-infective agents
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bacterial infections; Urinary tract infections
Most Recent Events
- 17 Mar 2025 Venatorx Pharmaceuticals completes a phase-I trial (In volunteers) in USA (PO) (NCT06665555),
- 07 Jan 2025 Venatorx Pharmaceuticals initiates a phase I pharmacokinetics trial (In volunteers) (PO, Capsule) (NCT06733675)
- 13 Dec 2024 Venatorx Pharmaceuticals plans a phase I pharmacokinetic trial (In volunteers) (PO, Capsule) in January 2025 (NCT06733675)